As the Democratic Republic of the Congo grapples with the fastest-growing Ebola outbreak on record, caused by the Bundibugyo virus (BDBV), GeoVax Labs, Inc. (Nasdaq: GOVX) has underscored the potential relevance of its MVA-based hemorrhagic fever vaccine expertise. With more than 4,300 cases and 2,000 deaths reported, the outbreak is on a trajectory that could surpass the devastation of the 2014-2016 West Africa epidemic, according to the World Health Organization (WHO). Currently, no approved vaccine specifically targets Bundibugyo virus.
GeoVax, a biotechnology company developing vaccines and immunotherapies, has extensive experience in creating vaccines against high-consequence hemorrhagic fever viruses using its Modified Vaccinia Ankara (MVA) platform. The company's portfolio includes vaccine candidates against Zaire ebolavirus, Sudan ebolavirus, and Marburg virus, all of which have shown encouraging protective efficacy in non-human primate lethal-challenge studies.
David Dodd, Chairman and Chief Executive Officer of GeoVax, stated, "The rapidly escalating Ebola Bundibugyo outbreak underscores the importance of having vaccine technologies and capabilities available before a crisis occurs. We are prepared to engage with WHO, Africa CDC, national public health authorities, and other appropriate organizations to determine whether our vaccine candidates, technology, or scientific expertise could contribute to the response. Where appropriate, we are also willing to make relevant vaccine materials available for evaluation against Bundibugyo virus."
GeoVax's lead infectious disease priority remains GEO-MVA, its MVA-based vaccine for mpox and smallpox prevention. The company is preparing to initiate a pivotal clinical development program based on an immunobridging accelerated regulatory pathway, with portions expected to be conducted in African regions facing significant infectious disease challenges, including areas affected by the current Ebola outbreak. As part of these preparations, GeoVax is already engaging with healthcare, research, and public health organizations in the region, including those involved in the Ebola response. These relationships provide a natural opportunity to explore how GeoVax's scientific expertise, MVA platform capabilities, and existing hemorrhagic fever vaccine candidates could contribute to the public health response.
In parallel with GEO-MVA, GeoVax retains a portfolio of MVA-based hemorrhagic fever vaccine candidates that have demonstrated protective efficacy in animal challenge models. These programs represent potential strategic optionality beyond GEO-MVA. The company is open to discussing collaborations, licensing arrangements, public-private partnerships, and other strategic structures that could provide resources and expertise for further evaluation and development of these assets without diverting primary resources from GEO-MVA.
GeoVax believes its combination of MVA platform expertise, hemorrhagic fever vaccine candidates, and work to advance scalable MVA manufacturing provides a foundation for potential collaborations addressing Ebola and other emerging infectious disease threats. The company's broader strategy includes innovations to address historical limitations associated with MVA vaccines, such as a continuous cell-line manufacturing process designed to improve scalability and production efficiency, evaluation of approaches that may enable a single-dose regimen, and exploration of microarray patch delivery technology. These initiatives support GeoVax's strategy to establish an independent and scalable source of MVA vaccine supply while building a broader platform capable of addressing current and emerging infectious disease threats.
